Zoledronic Acid-Mannitol-Water (zoledronic acid in mannitol and water for injection)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Zoledronic acid, a synthetic imidazole bisphosphonate analog of pyrophosphate, is a bone resorption inhibitor.
Zoledronic acid, a synthetic imidazole bisphosphonate analog of pyrophosphate, is an inhibitor of osteoclast-mediated bone resorption. Zoledronic acid is structurally and pharmacologically related to alendronate, risedronate, and pamidronate.
Zoledronic acid inhibits increased osteoclastic activity and skeletal calcium release induced by tumors. In patients with hypercalcemia of malignancy, zoledronic acid decreases serum calcium and phosphorus and increases urinary calcium and phosphorus excretion.
Zoledronic acid is eliminated in urine as unchanged drug. In patients with cancer and bone metastases, an average of 39% of an IV dose of zoledronic acid was excreted in urine within 24 hours. Nonrenal clearance is believed to result from uptake of the drug by bone; subsequently, the drug is released systemically via bone turnover.
Results of in vitro studies indicate that zoledronic acid does not inhibit the cytochrome P-450 (CYP) enzyme system.
USES: This medication is used to treat a certain type of bone disease (Paget's disease) that causes abnormal and weak bones. Zoledronic acid is also used to treat bone loss (osteoporosis) in men and in women after menopause who are at high risk of having broken bones (fractures). It may also be used to treat or prevent osteoporosis in people who are taking corticosteroid medications (such as prednisone) for long periods.
It works by slowing the breakdown of bone and keeping bones strong. It also helps to reduce the risk of broken bones (fractures). This medication belongs to a class of drugs known as bisphosphonates.
Generic name: zoledronic acid in mannitol and water for injection
Pronunciation: (ZOLE-eh-dron-ick)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Zoledronic Acid-Mannitol-Water
Indications
The following indications are listed for Zoledronic Acid-Mannitol-Water:
- Glucocorticoid-Induced Osteoporosis
- Osteoporosis In Male Patient
- Osteoporosis In Postmenopausal Woman At High Risk For Fracture
- Paget's Disease Of Bone
- Post-Menopausal Osteoporosis Prevention
- Prevention Of Glucocorticoid-Induced Osteoporosis
Also known as: Glucocorticoid Hormone-Induced Osteoporosis, Glucocorticoid Induced Osteoporosis, Glucocorticoid-Induced Osteoporosis Prophylaxis, Glycocorticoid-Induced Osteoporosis, Osteitis Deformans, Osteoporosis In Men, Postmenopausal Osteoporosis In Woman With High Fracture Risk, Postmenopausal Osteoporosis Prophylaxis, Postmenopausal Osteoporosis With High Fracture Risk.
Dosing
Dosage of zoledronic acid, which is commercially available for parenteral use as the monohydrate, is calculated on the anhydrous basis.
Zoledronic acid is administered by IV infusion over no less than 15 minutes. (See Renal Effects under Cautions: Warnings/Precautions.)
Zoledronic acid is commercially available as a solution concentrate containing 4 mg of the drug per 5 mL (Zometa(R) concentrate or generic equivalents) and as a ready-to-use injection containing 4 mg of the drug per 100 mL (Zometa(R) ready-to-use or generic equivalents) for use in patients with cancer-related indications. Zoledronic acid also is available as a ready-to-use injection containing 5 mg of the drug per 100 mL (Reclast(R) or generic equivalents) for use in the prevention or treatment of osteoporosis or for treatment of Paget disease of bone.
Zoledronic acid should be administered through separate vented infusion lines apart from other drugs and should not be allowed to come in contact with any solutions containing calcium or other divalent cations.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to zoledronic acid, other bisphosphonates, or any ingredient in the formulations.
Hypocalcemia.
Use of zoledronic acid for prevention or treatment of osteoporosis or for treatment of Paget disease of bone is contraindicated in patients with creatinine clearance of less than 35 mL/minute or those with evidence of acute renal impairment.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Zoledronic acid is not indicated for use in children.
Category D. (See Users Guide and see Fetal/Neonatal Morbidity and Mortality under Cautions: Warnings/Precautions.)
It is not known whether zoledronic acid is distributed into milk; because of the potential for serious adverse effects in nursing infants from zoledronic acid, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman. It is also important to consider that zoledronic acid is retained by bone for prolonged periods and may be released over weeks to years, possibly affecting nursing infants.
No overall differences in safety and efficacy of zoledronic acid relative to younger adults; however, the incidence of acute-phase inflammatory reactions was less in geriatric patients with osteoporosis or Paget disease of bone than in younger adults. Because of the greater frequency of impaired renal function in geriatric patients, the manufacturer states that renal function should be monitored with particular care in this age group.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.